Business Standard

Ind-Swift Labs to sell pharma ingredients ops to Synthimed Labs for $198 mn

Ind-Swift Labs will sell its active pharmaceuticals ingredients (API) and contract research and manufacturing services (CRAMS) business

pharmaceutical sector, pharma sector, medicines, meds

Photo: Bloomberg

Reuters BENGALURU

Listen to This Article

BENGALURU (Reuters) - India's Ind-Swift Laboratories said on Wednesday it would sell its active pharmaceuticals ingredients (API) and contract research and manufacturing services (CRAMS) business to Synthimed Labs in a deal with an enterprise value of 16.50 billion rupees ($198.50 million). ($1 = 83.1238 Indian rupees)

 

(Reporting by Ashish Chandra in Bengaluru; Editing by Savio D'Souza)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 06 2023 | 2:51 PM IST

Explore News